

**SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
DIRECCIÓN DE NUEVAS CREACIONES**

2020
Bogotá, D.C.,

Abogado

(**DILIA RODRÍGUEZ D'ALEMAN**

Apoderado

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 07-034647- -00003-0000

Fecha: 2010-09-30 12:18:50 Dep. 2020 DIR.NUEVASCR
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 519 TRASLADOINFORME Folios: 1

ASUNTO

Radicación 07-034647

Trámite 002

Evento 001

Actuación 430

Oficio

Folios **1 2 0 4 2**
09

Patente de Invención

☐

Patente de Modelo de Utilidad

☐

Vía Nacional

☐

Vía PCT (fase nacional)

☐

Cap.I

☐

Cap. II

☐

No. Sol. Internacional

PCT/MX2004/000064

Fecha de Presentación Internal.

09 de septiembre de 2004

Como resultado del examen de fondo, realizado con fundamento en el artículo 45 de la Decisión 486 de la Comisión de la Comunidad Andina, se le comunica:

1. Documentos estudiados

Descripción:

Folios: 5 a 12 como se radicó inicialmente

Reivindicaciones:

Folios 13 a 14 como se radicó inicialmente

Dibujos:

Folios 15 a 18 como se radicó inicialmente

Prioridad:

No

2. Objeto de la invención

Título de la solicitud: Composición farmacéutica de liberación prolongada de hidralazina y su uso como apoyo para el tratamiento del cáncer

El problema planteado en esta solicitud es la necesidad de obtener composiciones de liberación prolongada de hidralazina, con una liberación constante del fármaco durante un tiempo cercano a las 20-22 horas y después una disminución de la velocidad hasta las 24 horas.

Para solucionar este problema técnico la solicitud en estudio, el solicitante proporciona composiciones de liberación prolongada de hidralazina a una velocidad de liberación 7.58mg/hora

IPC: A61K 9/22

3. De la solicitud de Patente

Reivindicaciones (artículo 30 D 486)

El solicitante en la reivindicación 2 se refiere a “entre otros” polímeros, sin limitarla indicando que cualquier otro polímero puede ser usado en la composición objeto de la solicitud. Así mismo sucede con la reivindicación 6.

La reivindicación 7 referida a composiciones, no es clara, porque caracterizan su uso, el cual no es una característica técnica de la composición.

Se sugiere restringir las composiciones reivindicadas a una razonable generalización de aquellas que se encuentran sustentadas en la descripción, y que corresponden con los resultados presentados.

Se sugiere al solicitante modificar el título a “Composición farmacéutica de liberación prolongada de hidralazina”, puesto el uso no es patentable de acuerdo con la legislación vigente (D486)

4. Determinación del Estado de la Técnica

La fecha que se ha tenido en cuenta para determinar el Estado de la Técnica es:

- Fecha de la publicación en fase internacional :16 de marzo de 2006

Considerando que la fecha de presentación de la primera solicitud de patente de la cual se reivindica prioridad es: 16/03/2006 se encontraron los siguientes documentos del estado de la técnica relacionados, que pueden afectar la patentabilidad del objeto de la presente solicitud:

Nº	Documento	Título	Fecha de publicación
D1	US 4,521,402	Constant release rate solid oral dosage formulations of hydralazine	04/06/1985

5. Análisis de patentabilidad (artículo 14 D486)

Nivel inventivo (artículo 18 D486)

La reivindicación 1 consiste en:

Una composición farmacéutica de liberación prolongada de hidralazina, caracterizada porque comprende: del 10 al 70% de clorhidrato de hidralazina como principio activo; de 3 a 50% de un polímero limitante de la velocidad de liberación de dicho principio activo; de 15-40% de un agente diluyente; del 5 al 20% de un polímero hidrofílico moderador de la velocidad de liberación; y entre 0.1 al 2% de un agente lubricante.

El Estado de la Técnica más cercano es **D1**, que da a conocer composiciones de liberación constante de hidralazina la cual puede estar en su sal (clorhidrato) en una proporción terapéuticamente efectiva (69.0%- Ejemplo 3, Ver columna 6), 0.5-6.0% de un polímero hidrofóbico y ácido-retardante (Ver columna 3, líneas 38-42, Ver reivindicación 1, columna 9; un agente diluyente (Ver columna 3, líneas 42-46, Ejemplo 3, Ver columna 6); 1-20% de un polímero hidrofílico (ácido acrílico, carbómero, ver columna 3, líneas 24-26 y entre 0.4-3% de un agente lubricante.(Ver columna 3, líneas 34-36, Ver reivindicación 1, columna 9)

Las composiciones objeto de esta solicitud se diferencian de las formulaciones de **D1**, en las proporciones empleadas y la cantidad de diluyente empleada.

El hecho de incluir estas diferentes sustituciones en los compuestos que se daban a conocer en **D1**, causa que las composiciones de liberación prolongada de hidralazina sean útiles para el tratamiento de cáncer con una liberación constante del fármaco durante un tiempo cercano a las 20-22 horas y después una disminución de la velocidad hasta las 24 horas.

El Problema Técnico Objetivo era obtener composiciones de liberación prolongada de hidralazina para el tratamiento de cáncer con una liberación constante del fármaco durante un tiempo cercano a las 20-22 horas y después una disminución de la velocidad hasta las 24 horas.

Solicitud presentada	D1 US 4,521,402
REIVINDICACIÓN 1	
Composición farmacéutica de liberación prolongada: hidralazina 10-70%	Cantidad terapéuticamente efectiva o su sal 69%-Ejemplo 3, Ver columna 6 Ver resumen Clorhidrato Ver ejemplos 3 y 4, columna 6 Ver reivindicación 1, columna 9
3-50% polímero limitante	0.5-6.0% Ver columna 3, líneas 38-42 Ver reivindicación 1, columna 9
15 a 40% agente diluyente	6.90% Ejemplo 3, Ver columna 6 Ver columna 3, líneas 42-46 Ver reivindicación 1, columna 9
5 al 20% de un polímero hidrofílico	1-20% Ácido acrílico, carbómero Columna 3, líneas 24-26 3.45% Carbopol (Carbómero)-Ejemplo 3 Ver columna 6 Ver reivindicación 1, columna 9
0.1 al 2% de un agente lubricante	0.4-3% Ver columna 3, líneas 34-36 Ver reivindicación 1, columna 9
REIVINDICACIONES DEPENDIENTES	
Polímero limitante: etilcelulosa, hidroxipropilcelulosa, hidroxipropilmetilcelulosa, hidroxietilcelulosa, derivados del ácido metacrílico, entre otros. (Reivindicación 2)	Etilcelulosa, Ver columna 3, líneas 38-42 Celulosa acetato Ver ejemplo 4, columna 4
Agente diluyente: Almidón, lactosa, celulosa microcristalina, fosfato de calcio monobásico o dicálcico, alcoholes derivados de carbohidratos como sorbitol o manitol o mezclas de todos los anteriores (Reivindicación 3)	Ver columna 3, líneas 34-36 6.90%-Lactosa-Celulosa microcristalina Ejemplo 3, Ver columna 6
Polímero hidrofílico: Almidón y sus derivados, derivados alquilados de celulosa como metilcelulosa, carboxi metilcelulosa, carbómero, gomas naturales como goma acacia o xantana,	Carbopol (Carbómero) Ejemplo 3, Ver columna 6

polivinilpirrolidona, carragenina o mezclas de algunos de los anteriores (Reivindicación 4)	
Lubricante: Estearato de magnesio, ácidos grasos de cadena larga como esteárico, palmítico y oleico entre otros, o una mezcla de algunos de los anteriores. (Reivindicación 5)	Estearato de magnesio, ácidos grasos de cadena larga como esteárico Columna 4, líneas 7-11 Ejemplo 3, Ver columna 6
Solvente para granulación: a base de agua, alcoholes orgánicos de cadena corta, glicoles y trioles entre otros.	Alcohol isopropílico Ejemplo 3, Ver columna 6

La reivindicación es obvia, porque el Experto en la Materia enfrentado al problema de obtener “composiciones de liberación prolongada de hidralazina para el tratamiento de cáncer con una liberación constante del fármaco durante un tiempo cercano a las 20-22 horas y después una disminución de la velocidad hasta las 24 horas”, emplearía los mismos excipientes que se revelan en **D1**, modificando sus proporciones de acuerdo con el conocimiento medio de un experto en la materia, logrando de esta forma las composiciones objeto de esta solicitud. Por lo tanto, la reivindicación 1 no tiene Nivel Inventivo. Las reivindicaciones dependientes 2 –7, no mencionan alguna característica que haga inventivas a las composiciones de la reivindicación 1, por lo cual se considera que no tienen nivel inventivo.


6. Conclusión:

Los requisitos de patentabilidad de la presente solicitud se encuentran afectados así:

Nº	Documento Nº	Reivindicaciones afectadas	Requisito que afecta
D1	US 4,521,402	1-7	Nivel Inventivo

En cumplimiento del artículo 45 de la Decisión 486 de la Comisión de la Comunidad Andina, se le indica que debe dar respuesta dentro del término de sesenta días contados a partir de la fecha de notificación de la presente comunicación. En caso de no dar respuesta al presente requerimiento, o si a pesar de la respuesta subsistieran los impedimentos para la concesión, se denegará la patente.

Notifíquese el presente oficio conforme a lo dispuesto en el numeral 5.2, literal e), del capítulo quinto del título primero de la Circular Única Nº 10 de 2001.


ALIX CARMENZA CÉSPEDES DE VERGEL
Directora de Nuevas Creaciones (C)

El anterior requerimiento fue notificado por fijación en lista, de fecha

21 OCT. 2010

CONCEPTO TÉCNICO No. 03024	EXAMINADOR TÉCNICO Código No. 202070
----------------------------	---

DI 49

United States Patent [19]
Dunn

[11] **Patent Number:** **4,521,402**
[45] **Date of Patent:** **Jun. 4, 1985**

[54] **CONSTANT RELEASE RATE SOLID ORAL
DOSAGE FORMULATIONS OF HYDRAZINE**

- [75] **Inventor:** James M. Dunn, Littleton, Colo.
[73] **Assignee:** Verex Laboratories, Inc.,
Englewood, Colo.
[21] **Appl. No.:** 581,368
[22] **Filed:** Feb. 17, 1984

Related U.S. Application Data

- [62] Division of Ser. No. 455,192, Jan. 3, 1983.
[51] **Int. Cl.³** A61K 9/22; A61K 9/26
[52] **U.S. Cl.** 424/19; 424/22
[58] **Field of Search** 424/19-22

References Cited

U.S. PATENT DOCUMENTS

- | | | | |
|-----------|--------|----------------|---------|
| 3,400,197 | 9/1968 | Lippmann | 424/357 |
| 4,248,856 | 2/1981 | Guley et al. | 424/21 |
| 4,248,857 | 2/1981 | DeNeale et al. | 424/21 |
| 4,248,858 | 2/1981 | Guley et al. | 424/21 |

OTHER PUBLICATIONS

- Liedholm et al., C.A. 98, #78050j, (1983).
Hisosaka et al., C.A. 96, #205433x, (1982).
Talseth et al., C.A. 86, #195134c, (1977).

Primary Examiner—Shep K. Rose
Attorney, Agent, or Firm—Niblack & Niblack

[57] **ABSTRACT**

A constant order release rate solid oral dosage formulation of hydralazine or a pharmaceutically acceptable salt thereof, said formulation comprising: a therapeutically effective amount of hydralazine or a pharmaceutically acceptable salt; from about 0.5 to 6.0 weight percent of an acid-retardant or hydrophobic cellulose derivative; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil; from about 1 to 20 weight percent of an acrylic acid polymer; from about 0.5 to 4.0 weight percent of fumed silicon dioxide and from about 0.4 to 3.0 percent of a lubricant.

8 Claims, No Drawings

CONSTANT RELEASE RATE SOLID ORAL DOSAGE FORMULATIONS OF HYDRAZINE

BACKGROUND OF THE INVENTION

This is a division of application Ser. No. 455,192, filed Jan. 3, 1983.

The present invention relates to improved pharmaceutical formulations and more specifically relates to constant release rate solid oral dosage formulations of hydralazine or a pharmaceutically acceptable salt thereof.

It is an axiom in pharmaceutical science that in order for a drug in an oral solid dosage formulation to be absorbed, it must first become soluble in the aqueous media of the stomach or small intestine. Products which are rapidly dissolved in water are also rapidly absorbed into the body. For such products, controlling their rate of solvation after ingestion also influences their rate of absorption, and drugs which are highly or moderately water-soluble present special formulation problems.

Formulations which effectively control the rate of solvation of highly water soluble drugs are disclosed and claimed in commonly assigned, copending U.S. patent application Ser. No. 443,397, filed Oct. 8, 1982. See also commonly assigned, copending U.S. patent application Ser. No. 364,014 filed Mar. 31, 1982 for constant order release theophylline formulations, allowed U.S. Ser. No. 366,594, filed Apr. 8, 1982 for constant order release aspirin formulations and U.S. Ser. No. 334,124 filed Dec. 24, 1981 for constant release indomethacin formulations. The above commonly assigned, copending application discloses constant order release solid oral dosage formulations which provide a smooth onset of drug action with a subsequent longer duration of pharmacological activity and avoid the peaks and valleys of activity and side effects of drugs administered in conventional formulations, including conventional timed-release formulations. It was also recognized that in view of the number of factors which successfully overcomes the properties peculiar to a specific drug or a group of drugs which share given properties, simply is not suitable for all drugs for the following reasons.

A second factor influencing drug absorption after solubility has occurred is the passage of the drug across the intestinal membrane. A drug generally crosses several membranes to reach its receptor site. This transfer is usually accomplished by passive diffusion. Special transport mechanisms such as facilitated diffusion and active transport allow some substances to cross cell membranes at a faster rate than simple diffusion. By far, however, the most common mechanism for transport of a drug in solution across the intestinal wall is by passive diffusion.

Passive diffusion is characterized by the movement of the drug molecule down a concentration or electrochemical gradient without the expenditure of cellular energy. The transfer process is neither saturable nor inhibited by other materials and is only slightly sensitive to temperature changes. Since most cells in the gastrointestinal tract are in close proximity to capillaries, the passage of drugs across short distances is usually rapid.

The driving force for passive drug transport is the difference between the concentration of the diffusing drug in the intestinal tract and the concentration gradient of the drug on the other side of the plasma membrane. The rate of drug penetration corresponds to the

concentration gradient and is characterized by Fick's law.

Many drugs are either an organic acid or a base. Acids donate a hydrogen ion to form a negatively charged anion, while bases accept a hydrogen ion to form a positively charged cation. It is usually assumed that only nonionized, lipid-soluble drugs pass through the lipid rich membranes of the intestinal tract. The ionized molecule is thought to be too polar to penetrate this lipoidal barrier. If it does cross the cell wall, it does so at a slow rate. This concept of drug absorption is known as nonionic diffusion.

An extension of this theory is the pH partition hypothesis, which asserts that the passage rate of a drug through a membrane is dependent upon the pH of the drug's environment and the dissociation constant, or " pK_a " of the drug. The pK_a is expressed as the pH at which 50% of the drug will be in the ionized form and 50% will be in the nonionized form. Diffusion of acids and bases across the membrane is not always influenced by pH, as in the case of weak acids or bases. These types of products are essentially completely nonionized at all physiologic pH values. At the other extreme however, are strong acids and bases which are almost completely ionized, and their transfer is dependent upon the pH at which they become dissolved and subsequently become ionized or nonionized.

An example of pH partition hypothesis may be explained by the fact that aspirin, which has a pK_a or dissociation constant of between 3 and 3.7 becomes very nonionized in the acid media of the stomach and subsequently is rapidly absorbed from the gastric mucosa, where the pH is between 1 and 3. As the drug particles pass into the small intestines where the pH increases and the rate of ionization is changed so absorption is subsequently slowed. Conversely strong bases such as ephedrine, which has a pK_a of 9.3, or amphetamine with a pK_a of 9.9 are almost negligibly absorbed from the acidic gastric contents, but are absorbed rather rapidly from the intestinal fluid which has a much lower hydrogen ion concentration. By controlling the release of a drug from the tablet matrix one can control the rate of solvation. The rate of absorption for those products having a pK_a above 7 will be greatest, once they reach the small intestine.

While the pH partition hypothesis and nonionic diffusion cannot entirely account for drug absorption, however it is one factor to consider among the various factors controlling the rate and mechanism of drug absorption in the intestinal tract.

The present invention provides formulations for drugs with a basic nature ie: pK_a 7-10. The formulations of the present invention release their contents in a rather constant manner in the small intestine, thereby controlling the rate at which passive diffusion can occur. While commonly assigned, co-pending U.S. patent application Ser. Nos. 443,497; 364,014; 366,594 and 334,124 disclose various constant release formulations, the present invention provides formulations which take into account the pH partition and which will release basic drugs into the small intestines at a constant and controlled rate, thereby controlling their serum level and prohibiting the peaks and valleys or erratic absorption which may be obtained with standard formulations.

SUMMARY

This invention provides constant order formulations of the cardiovascular agent hydralazine or a pharmaceutically acceptable salt thereof solubility of 100 gm/ml.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The present invention provides a constant order release, solid oral dosage formulation of the cardiovascular drug hydralazine or a pharmaceutically acceptable salt thereof, said formulation comprising a therapeutically effective amount of said drug, the drug particles being coated with from about 2.5 to about 6 weight percent of an acid-retardant cellulose derivative, preferably from 0.8 to 4.6 weight percent; in a lipid-polymer matrix. The lipid comprises from 2.5 to 35.0 weight percent of the composition, preferably between 7.0-25.0 weight percent. The preferred lipids are hydrogenated vegetable oil and the preferred hydrogenated vegetable oil is a hydrogenated cotton seed oil sold under the mark LUBRITAB by E. Mendell Corporation. The preferred acid polymer is an acrylic acid polymer, carboxypolymethylene (carbomer) sold under the trademark CARBOPOL-934-P by B.F. Goodrich. The acid polymer is present in amounts ranging from 1 to 20 weight percent of the formulation, preferably from about 2.5 to 12 weight percent. The composition of the present invention additionally comprises an anti-sticking agent, preferably fumed silicon dioxide sold under the mark SYLOID-244 by W. Grace Company in amounts of between 0.5-4.0 weight percent of the composition and from 0.4 to 3.0 weight percent of a tableting lubricant such as magnesium stearate, talc, stearic acid and the like.

The preferred acid-retardant and hydrophobic cellulose derivatives include, but are not limited to, cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, ethylcellulose and the like. Such agents are well known in the art.

In addition, the formulations of the present agent may optionally include bulking agents and disintegrants, depending upon the desired release characteristic of the finished product. Such agents are optional, and not critical to the present formulations.

The formulations of this invention retard the release of the active drug in the gastric juices where there is a low pH and subsequently there would be a high degree of nonionized material available, which would result in rapid absorption of the drug product. Controlling the drug release is accomplished by the incorporation of an acid resistant cellulose derivative preferably cellulose acetate phthalate or hydroxypropylmethyl cellulose phthalate into the formulation.

The lipid complex component of the present formulation slows the solvation rate of the drug as it enters the more neutral to alkaline media of the small intestine. Although there will be a shift in the dissociation constant producing more ionized drug, the incorporation of the drug product into a lipid material offsets the changes in dissociation constant facilitating the absorption of the ionized fragments by the inherent lipophilicity of the solvated material. This lipid content also controls the rate of drug release from the tablet matrix further assuring a controlled and constant release rate product. By utilizing a hydrophobic cellulose derivative

the rate of drug dissolution and solvation is also controlled.

It is important to note that compositions containing polymers of acrylic acid in conjunction with hydrogenated vegetable oil are mechanically difficult to press into a tablet without considerable weight variation in the tablets or sticking to the tablet punches. The classical tableting lubricants such as talc, magnesium stearate, stearic acid, cetyl alcohol, calcium stearate or zinc stearate are ineffective in alleviating this problem. It was found that the only suitable solution to the problem was the inclusion of 0.5 to 4.0 weight percent of fumed silicon dioxide, sold under the trademark SYLOID-244 by W. Grace Company. This both alleviates the problem of tablet sticking and serves as superior lubricant.

Turning to the preferred process of the present invention, all materials are weighed and blended for 15 minutes for each 40 kilograms of dry material. Isopropyl alcohol which may constitute 35-60 weight percent is slowly added at a rate of 3 minutes per liter of solvent. If ethylcellulose is to be dispersed in the solvent prior to granulation, the cellulose derivative should be blended until there is complete dispersion and clarity of the solution. Generally, it will take between 35-40 minutes per 125 liters of fluid using a lightening blender to effect complete dispersion and solvation of the ethylcellulose. It is critical that the wet granulation be completely dried before screening. Failure to observe this technique may result in rupture of the granules and a loss of the constant release rate profile of the resulting tablets. In conventional prior art methods, the wet granulations are generally screened immediately after formation, then dried. If the prior art processes are employed, the constant release rate profile of the tablets may be destroyed.

When cellulose acetate phthalate is employed in formulations of the present invention, it is important to granulate the drug and cellulose acetate phthalate, and/or bulking agent or disintegrant if such agents are employed, with the solvents and subsequently add the remainder of the ingredients. Otherwise, a viscous, rubbery mixture which cannot be tableted with be obtained.

The following examples further illustrate the present invention.

EXAMPLE 1

Quinidine sulfate tablets weighing 362 mg are prepared from the following formulation:

1. Quinidine Sulfate	300 gm
2. Hydrogenated Cotton seed oil	25 gm
3. Carbopol - 934p	10 gm
4. Microcrystalline cellulose	
5. Cellulose acetate phthalate	9 gm
6. Syloid 244	10 gm
7. Magnesium stearate	5 gm
8. Methylene chloride	25 ml
9. Isopropyl alcohol	100 ml
	362 gm

In the above formulation quinidine sulfate, dibasic calcium phosphate, and microcrystalline cellulose are blended in a Hobart mixer. The cellulose acetate phthalate is dissolved in methylene chloride and isopropyl alcohol until a clear solution is achieved. The dry blend is then granulated with the solvent-cellulose solution until a well formed granulate is produced. The product

is dried at 100° F. and then passed through a #18 mesh screen blended with magnesium stearate and compressed into capsule-shaped tablets weighing 362 mg, with a hardness of 10-12 kp. These tablets were then placed in a standard U.S.P. disintegration apparatus without discs and a gastric solution with a pH of 1.2-1.4. The amount of mean weight loss in 6 tablets over 3 hours is shown below.

	DISINTEGRATION % pH 1.2-1.4			
	0 HR	1 HR	2 HR	3 HR
1.	414 mg	410	407	400
2.	416 mg	412	406	398
3.	412 mg	406	405	399
4.	413 mg	408	402	392
5.	417 mg	412	409	389
6.	414 mg	410	403	395
mean	414.3	409.6	405.3	395.5
S.D. +	1.86	2.3	2.6	4.3
% Loss	0	1.13%	2.2%	4.8%

This demonstrates that after 3 hours of agitation in gastric acid media the tablets lost less than 5% of their weight.

Tablets from this same batch were tested for dissolution using a U.S.P. apparatus II at 50 rpm and pH 7.5. The following are the results from that test expressed as % of drug dissolved:

	DISSOLUTION % OF DRUG DISSOLVED					
	1 HR	2 HR	3 HR	4 HR	5 HR	6 HR
1.	23%	31%	42%	56%	62%	75%
2.	25%	30%	43%	52%	65%	73%
3.	26%	29%	44%	53%	61%	76%
4.	22%	33%	46%	55%	67%	77%
5.	19%	32%	41%	51%	60%	74%
6.	21%	31%	40%	54%	63%	72%
mean %	22.7%	31.0%	42.7%	53.5%	63.0%	74.5%
S.D. +	2.58	1.40	2.16	1.87	2.61	1.87

This study demonstrates the behavior of the tablets in a more neutral to alkaline media. Using linear regression analysis on the above information, a constant release rate pattern is demonstrated. The correlation coefficient (r value) slope and intercept are shown below.

ANALYSIS BY LINEAR REGRESSION

$$r = 0.999$$

$$\text{slope} = 0.096$$

$$\text{intercept} = -1.076$$

EXAMPLE 2

Quinidine sulfate tablets weighing 430 gm are prepared from the following formulation.

1. Quinidine sulfate	300 gm
2. Hydrogenated cotton seed oil	100 gm
3. Carbopol-934P	10 gm
4. Ethylcellulose (100 cps)	10 gm
5. Fumed silicon dioxide	5 gm
6. Magnesium stearate	5 gm
7. Isopropyl alcohol	100 gm
	430 gm

The quinidine, hydrogenated cotton seed oil and microcrystalline cellulose are blended. Ethylcellulose is dissolved with agitation in isopropyl alcohol. After complete dispersion, the solvent-cellulose solution is

used to granulate the quinidine, cottonseed oil and microcrystalline cellulose. After a granulate is formed it is completely dried at 100° F., passed through a #18 mesh screen and compressed into tablets weighing 430 mg containing 300 mg of quinidine sulfate with a hardness of 10-12 kp.

EXAMPLE 3

Hydralazine tablets weighing 580 mg and containing 400 mg of active drug are prepared from the following formulation.

1. Hydralazine hydrochloride	400 gm
2. Lactose	40 gm
3. Hydrogenated cotton seed oil	100 gm
4. Carbopol 934-P	20 gm
5. Microcrystalline cellulose	10 gm
6. Fumed silicon dioxide	7 gm
7. Magnesium stearate	3 gm
8. Isopropyl alcohol	250 gm
	580 gm

Hydralazine, lactose, hydrogenated cottonseed oil Carbopol 934-P and microcrystalline cellulose are placed in a Hobart mixer and thoroughly blended. A wet granulation is then made by adding slowly the isopropyl alcohol while blending. After a granulate is formed, it is air dried at 100° F. and passed through a number #16-#18 mesh screen and blended with the silicon dioxide and magnesium stearate. Tablets are then compressed from the granulate to form a capsule shaped tablet weighing 580 mg and containing 400 mg of hydralazine. The tablets have a hardness of 10-12 kp.

EXAMPLE 4

Hydralazine tablets weighing 530 mg and containing 200 mg of active drug are prepared from the following formulation.

1. Hydralazine hydrochloride	200 gm
2. Lactose	75 gm
3. Hydrogenated cotton seed oil	100 gm
4. Carbopol 934-p	20 gm
5. Cellulose acetate phthalate	25 gm
6. Microcrystalline cellulose	50 gm
7. Fumed silicon dioxide (Syloid-244)	6 gm
8. Magnesium Stearate	4 gm
9. Methylene Chloride	75 ml
10. Isopropyl alcohol	150 ml
	530 gm

Hydralazine, lactose, diisic calcium phosphate, Carbopol 934-P and microcrystalline cellulose are thoroughly blended in a Hobart mixer. The cellulose acetate phthalate is dissolved in methylene chloride and isopropyl alcohol until a clear solution is obtained, it is then added in a slow steady stream to the blended dry mixture until an overwet granule is formed. The granule is air dried at 100° F. and then passed through a #18 screen, mixed thoroughly with the silicon dioxide and magnesium stearate. Following this blending the granulate is compressed into tablets weighing 530 mg and containing 200 mg of hydralazine. The tablets have a hardness of 10-12 kp.

Tablets prepared according to the method of example 4 were placed in a USP disintegration apparatus with the fluid media being 1.2-1.4. After 3 hours of agitation there was less than a 10% reduction in tablet weight. Six tablets were randomly selected for dissolution testing in

57

through a #16 mesh screen and compressed into tablets having a hardness to 10-12 kp.

I claim:

1. A constant order release solid oral dosage formulation of hydralazine or a pharmaceutically acceptable salt thereof, said formulation comprising: a therapeutically effective amount of hydralazine or a pharmaceutically acceptable salt thereof; from about 0.5 to 6.0 weight percent of one or more cellulose derivatives selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethylcellulose, phthalate ethyl cellulose, and microcrystalline cellulose; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil; from about 1 to 20 weight percent of carboxypolymethylene; from about 0.5 to 4.0 weight percent of fumed silicon dioxide and from about 0.4 to 3.0 weight percent of a tableting lubricant.

2. The formulation of claim 1 wherein said cellulose derivative is a combination of cellulose acetate phthalate and microcrystalline cellulose.

3. The formulation of claim 1 wherein said hydrogenated vegetable oil is hydrogenated cottonseed oil.

4. The formulation of claim 1 wherein said cellulose derivative is microcrystalline cellulose.

5. The formulation of claim 1 wherein said cellulose derivative is a combination of cellulose acetate phthalate and microcrystalline cellulose, and said hydrogenated vegetable oil is hydrogenated cottonseed oil.

ate and microcrystalline cellulose, and said hydrogenated vegetable oil is hydrogenated cottonseed oil.

6. The formulation of claim 1 wherein said cellulose derivative is microcrystalline cellulose and said hydrogenated vegetable oil is hydrogenated cottonseed oil.

7. A constant order release solid oral dosage formulation of hydralazine or a pharmaceutically acceptable salt thereof comprising: a therapeutically effective amount of hydralazine or a pharmaceutically acceptable salt thereof; from 0.5 to 6.0 weight percent of a combination of microcrystalline cellulose and cellulose acetate phthalate; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil; from about 1 to 20 weight percent of carboxypolymethylene; from about 0.5 to 4.0 weight percent of fumed silicon dioxide and from about 0.4 to 3.0 weight percent of a tableting lubricant.

8. A constant order release solid oral dosage formulation of hydralazine of a pharmaceutically acceptable salt thereof comprising: a therapeutically effective amount of hydralazine or a pharmaceutically acceptable salt thereof; from 0.5 to 6.0 weight percent of ethyl cellulose; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil; from about 1 to 20 weight percent of carboxypolymethylene; from about 0.5 to 4.0 weight percent of fumed silicon dioxide; and from about 0.4 to 3.0 weight percent of a pharmaceutically acceptable tableting lubricant.

* * * * *

30

35

40

45

50

55

60

65